SG10201403568RA - Method of treating cancer with dll4 antagonist and chemotherapeutic agent - Google Patents
Method of treating cancer with dll4 antagonist and chemotherapeutic agentInfo
- Publication number
- SG10201403568RA SG10201403568RA SG10201403568RA SG10201403568RA SG10201403568RA SG 10201403568R A SG10201403568R A SG 10201403568RA SG 10201403568R A SG10201403568R A SG 10201403568RA SG 10201403568R A SG10201403568R A SG 10201403568RA SG 10201403568R A SG10201403568R A SG 10201403568RA
- Authority
- SG
- Singapore
- Prior art keywords
- chemotherapeutic agent
- treating cancer
- dll4 antagonist
- dll4
- antagonist
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Inorganic Chemistry (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22046509P | 2009-06-25 | 2009-06-25 | |
| US30188110P | 2010-02-05 | 2010-02-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201403568RA true SG10201403568RA (en) | 2014-10-30 |
Family
ID=42668243
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201403568RA SG10201403568RA (en) | 2009-06-25 | 2010-06-25 | Method of treating cancer with dll4 antagonist and chemotherapeutic agent |
| SG2011091642A SG176791A1 (en) | 2009-06-25 | 2010-06-25 | Method of treating cancer with dll4 antagonist and chemotherapeutic agent |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG2011091642A SG176791A1 (en) | 2009-06-25 | 2010-06-25 | Method of treating cancer with dll4 antagonist and chemotherapeutic agent |
Country Status (28)
| Country | Link |
|---|---|
| US (3) | US8518887B2 (ru) |
| EP (1) | EP2445528B1 (ru) |
| JP (2) | JP6038650B2 (ru) |
| KR (1) | KR101750723B1 (ru) |
| CN (1) | CN102481365A (ru) |
| AR (1) | AR077241A1 (ru) |
| AU (1) | AU2010266004B2 (ru) |
| BR (1) | BRPI1011818A2 (ru) |
| CA (1) | CA2766163C (ru) |
| DK (1) | DK2445528T3 (ru) |
| ES (1) | ES2556804T3 (ru) |
| HK (1) | HK1169328A1 (ru) |
| HR (1) | HRP20160045T1 (ru) |
| HU (1) | HUE026356T2 (ru) |
| IL (1) | IL216952A (ru) |
| ME (1) | ME02296B (ru) |
| MX (1) | MX2011013424A (ru) |
| MY (1) | MY173234A (ru) |
| PL (1) | PL2445528T3 (ru) |
| PT (1) | PT2445528E (ru) |
| RS (1) | RS54477B1 (ru) |
| RU (1) | RU2571220C2 (ru) |
| SG (2) | SG10201403568RA (ru) |
| SI (1) | SI2445528T1 (ru) |
| SM (1) | SMT201500315B (ru) |
| TW (1) | TWI513465B (ru) |
| UY (1) | UY32739A (ru) |
| WO (1) | WO2010151770A1 (ru) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO347649B1 (no) * | 2006-12-14 | 2024-02-12 | Regeneron Pharma | Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse. |
| TWI513465B (zh) | 2009-06-25 | 2015-12-21 | Regeneron Pharma | 以ｄｌｌ４拮抗劑與化學治療劑治療癌症之方法 |
| DK2488204T3 (en) | 2009-10-16 | 2016-06-06 | Oncomed Pharm Inc | Therapeutic combination and use of DLL4 antagonist antibodies and blood pressure lowering agents |
| WO2012092539A2 (en) * | 2010-12-31 | 2012-07-05 | Takeda Pharmaceutical Company Limited | Antibodies to dll4 and uses thereof |
| US8858941B2 (en) | 2011-09-23 | 2014-10-14 | Oncomed Pharmaceuticals, Inc. | VEGF/DLL4 binding agents and uses thereof |
| US10085987B2 (en) | 2012-01-27 | 2018-10-02 | Thomas Jefferson University | MCT protein inhibitor-related prognostic and therapeutic methods |
| US20150240240A1 (en) * | 2012-09-13 | 2015-08-27 | Thomas Jefferson University | Msf reprograms myofibroblasts toward lactate production and fuel anaerboic tumor growth |
| EP2914961A4 (en) * | 2012-10-31 | 2016-04-20 | Oncomed Pharm Inc | METHODS AND MONITORING A TREATMENT BY AN ANTAGONIST OF DLL4 |
| TW201438736A (zh) * | 2012-11-14 | 2014-10-16 | Regeneron Pharma | 以ｄｌｌ４拮抗劑治療卵巢癌之方法 |
| US10022372B2 (en) | 2013-04-19 | 2018-07-17 | Thomas Jefferson University | Caveolin-1 related methods for treating glioblastoma with temozolomide |
| CN106794219A (zh) * | 2014-02-19 | 2017-05-31 | 北京迈康斯德医药技术有限公司 | 趋化因子受体拮抗体及其联合疗法 |
| US20160176962A1 (en) | 2014-10-31 | 2016-06-23 | Oncomed Pharmaceuticals, Inc. | Combination Therapy For Treatment Of Disease |
| US11291630B2 (en) * | 2015-09-16 | 2022-04-05 | Centre National De La Recherche Scientifique (Cnrs) | Gelling compositions for treating malignant tumours and/or preventing tumour recurrence |
| US11339213B2 (en) | 2015-09-23 | 2022-05-24 | Mereo Biopharma 5, Inc. | Methods and compositions for treatment of cancer |
| CN110339350A (zh) | 2019-07-25 | 2019-10-18 | 广州中科蓝华生物科技有限公司 | 一种抗肿瘤的联合用药物组合物及其应用 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4980286A (en) | 1985-07-05 | 1990-12-25 | Whitehead Institute For Biomedical Research | In vivo introduction and expression of foreign genetic material in epithelial cells |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| WO1992022653A1 (en) | 1991-06-14 | 1992-12-23 | Genentech, Inc. | Method for making humanized antibodies |
| CN1547590A (zh) | 2000-10-13 | 2004-11-17 | ¸ | 人源化抗-LT-β-R抗体 |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US7138370B2 (en) | 2001-10-11 | 2006-11-21 | Amgen Inc. | Specific binding agents of human angiopoietin-2 |
| US20040101920A1 (en) | 2002-11-01 | 2004-05-27 | Czeslaw Radziejewski | Modification assisted profiling (MAP) methodology |
| MXPA06001634A (es) | 2003-08-13 | 2006-04-28 | Pfizer Prod Inc | Anticuerpos humanos modificados igf-1r. |
| US20080107648A1 (en) | 2005-12-16 | 2008-05-08 | Regeneron Pharmaceuticals, Inc. | Therapeutic methods for inhibiting tumor growth with DII4 antagonists |
| US20060134121A1 (en) | 2004-10-29 | 2006-06-22 | Gavin Thurston | DII4 antagonists, assays, and therapeutic methods thereof |
| EP1928486A2 (en) | 2005-09-01 | 2008-06-11 | Vasgene Therapeutics, Inc. | Methods for using and identifying modulators of delta-like 4 |
| US8329408B2 (en) * | 2005-10-31 | 2012-12-11 | Bayer Healthcare Llc | Methods for prognosis and monitoring cancer therapy |
| NZ593226A (en) * | 2006-01-11 | 2012-10-26 | Genomic Health Inc | Gene expression markers (efnb2) for colorectal cancer prognosis |
| JP2009539384A (ja) | 2006-06-06 | 2009-11-19 | ジェネンテック・インコーポレーテッド | 抗ｄｌｌ４抗体および抗ｄｌｌ４抗体使用の方法 |
| US20080014196A1 (en) * | 2006-06-06 | 2008-01-17 | Genentech, Inc. | Compositions and methods for modulating vascular development |
| BRPI0717431A2 (pt) * | 2006-09-29 | 2013-11-12 | Oncomed Pharm Inc | Composições e métodos de diagnóstico e tratamento do câncer |
| NO347649B1 (no) | 2006-12-14 | 2024-02-12 | Regeneron Pharma | Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse. |
| US20100119526A1 (en) * | 2007-01-26 | 2010-05-13 | Bioinvent International Ab | DLL4 Signaling Inhibitors and Uses Thereof |
| EP1958632A1 (en) * | 2007-02-14 | 2008-08-20 | Dan Stoicescu | Use of condensed pyrimidine derivatives for the treatment of autoimmune and inflammatory diseases |
| CA2735900A1 (en) * | 2008-09-19 | 2010-03-25 | Medimmune, Llc | Antibodies directed to dll4 and uses thereof |
| EP2356270B1 (en) * | 2008-11-07 | 2016-08-24 | Fabrus Llc | Combinatorial antibody libraries and uses thereof |
| TWI513465B (zh) | 2009-06-25 | 2015-12-21 | Regeneron Pharma | 以ｄｌｌ４拮抗劑與化學治療劑治療癌症之方法 |
-
2010
- 2010-06-24 TW TW099120547A patent/TWI513465B/zh not_active IP Right Cessation
- 2010-06-25 UY UY0001032739A patent/UY32739A/es unknown
- 2010-06-25 AR ARP100102269A patent/AR077241A1/es unknown
- 2010-06-25 RU RU2012102415/10A patent/RU2571220C2/ru not_active IP Right Cessation
- 2010-06-25 BR BRPI1011818A patent/BRPI1011818A2/pt not_active IP Right Cessation
- 2010-06-25 JP JP2012517770A patent/JP6038650B2/ja active Active
- 2010-06-25 CA CA2766163A patent/CA2766163C/en active Active
- 2010-06-25 WO PCT/US2010/039999 patent/WO2010151770A1/en active Application Filing
- 2010-06-25 HU HUE10728555A patent/HUE026356T2/en unknown
- 2010-06-25 KR KR1020127001947A patent/KR101750723B1/ko active IP Right Grant
- 2010-06-25 MY MYPI2011005985A patent/MY173234A/en unknown
- 2010-06-25 CN CN201080037619XA patent/CN102481365A/zh active Pending
- 2010-06-25 DK DK10728555.3T patent/DK2445528T3/en active
- 2010-06-25 RS RS20150865A patent/RS54477B1/en unknown
- 2010-06-25 PL PL10728555T patent/PL2445528T3/pl unknown
- 2010-06-25 ME MEP-2015-185A patent/ME02296B/me unknown
- 2010-06-25 AU AU2010266004A patent/AU2010266004B2/en active Active
- 2010-06-25 MX MX2011013424A patent/MX2011013424A/es active IP Right Grant
- 2010-06-25 PT PT107285553T patent/PT2445528E/pt unknown
- 2010-06-25 EP EP10728555.3A patent/EP2445528B1/en active Active
- 2010-06-25 US US12/823,680 patent/US8518887B2/en active Active
- 2010-06-25 ES ES10728555.3T patent/ES2556804T3/es active Active
- 2010-06-25 SI SI201031078T patent/SI2445528T1/sl unknown
- 2010-06-25 SG SG10201403568RA patent/SG10201403568RA/en unknown
- 2010-06-25 SG SG2011091642A patent/SG176791A1/en unknown
-
2011
- 2011-12-13 IL IL216952A patent/IL216952A/en not_active IP Right Cessation
-
2012
- 2012-10-15 HK HK12110142.2A patent/HK1169328A1/xx not_active IP Right Cessation
-
2013
- 2013-07-23 US US13/948,919 patent/US8840886B2/en active Active
-
2014
- 2014-08-12 US US14/457,968 patent/US20150064189A1/en not_active Abandoned
-
2015
- 2015-08-14 JP JP2015160020A patent/JP2016006101A/ja not_active Withdrawn
- 2015-12-15 SM SM201500315T patent/SMT201500315B/it unknown
-
2016
- 2016-01-14 HR HRP20160045TT patent/HRP20160045T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1169328A1 (en) | Method of treating cancer with dll4 antagonist and chemotherapeutic agent dll4 | |
| EP2417127A4 (en) | KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH THE SAME | |
| PL2434891T3 (pl) | Sposoby leczenia nowotworu złośliwego i stanów nienowotworowych | |
| EP2556071A4 (en) | KINASE INHIBITORS AND METHOD OF TREATING CANCER USING THE SAME | |
| PT2365802T (pt) | Microcápsulas de rapamicina e utilização para o tratamento de cancro | |
| IL218316A (en) | Use of tiny taxane-containing particles to treat cancer in combination with hedgehog inhibitors | |
| GB2467610B (en) | Elevator and method of use | |
| IL215251A0 (en) | Atropisomers of2-purinyl-3-tolyl-quinazolinone derivatives and methods of use | |
| EP2497471A4 (en) | USE OF BENZO-HETEROCYCLUS DERIVATIVES FOR PROPHYLAXIS AND TREATMENT OF CANCER OR FOR INHIBITION OF CANCER METASTAS | |
| EP2459344A4 (en) | ABRASIVE ARTICLE AND METHOD OF MANUFACTURE | |
| HRP20170225T1 (hr) | Fosfoplatini i njihova uporaba za liječenje karcinoma | |
| EP2171086A4 (en) | METHOD FOR THE DIAGNOSIS AND TREATMENT OF CANCER | |
| EP2295598A4 (en) | METHOD AND KIT FOR DETECTING CANCER, AND THERAPEUTIC AGENT FOR CANCER | |
| IL218230A0 (en) | Method of treating cancer | |
| EG27041A (en) | Method of manufacturing direct reduction iron and reduction firing apparatus | |
| IL219934A0 (en) | Quinazolin-4(3a)-one derivatives and methods of use thereof | |
| PL2319533T3 (pl) | Środek indukujący odporność i sposób wykrywania nowotworu | |
| EP2416788A4 (en) | IDENTIFICATION AND TREATMENT OF CANCER | |
| EP2709730A4 (en) | TREATMENT AND PROGNOSIS OF CANCER | |
| EP2136631A4 (en) | PROCESS FOR TREATING NEOPLASIA WITH A COMBINATION OF CHEMOTHERAPEAN AGENTS AND RADIATION | |
| EP2298309A4 (en) | ANTITUMORAL AGENT, KIT AND METHOD FOR THE TREATMENT OF CANCER | |
| IL211752A0 (en) | Antibody combinations and use of same for treating cancer | |
| RS55471B1 (sr) | Inhibitori kinaze i njihova upotreba za lečenje kancera |